SOGROYA Market Summary

Key Factors Driving SOGROYA Growth

1. Once-weekly dosing addresses the burden of daily GH injections: SOGROYA’s major commercial differentiator is its once-weekly subcutaneous administration, compared with conventional daily recombinant GH. Daily injections can create substantial treatment burden and adherence challenges, particularly because GH treatment may continue for years during childhood. A peer-reviewed review notes that long-acting GH formulations such as somapacitan were developed specifically to reduce injection burden and potentially improve adherence and treatment outcomes. In the US, Novo Nordisk highlights that weekly SOGROYA provides 313 injection-free days per year compared with 365 injections with daily therapy.

2. Rapid expansion of approved pediatric indications: A major growth catalyst is the expansion beyond conventional pediatric GHD. In February 2026, the FDA approved SOGROYA for children ≥2.5 years with idiopathic short stature (ISS), short stature after being born small for gestational age (SGA) without catch-up growth, and growth failure associated with Noonan syndrome. The approval was supported by the REAL8 Phase III program, where SOGROYA demonstrated non-inferiority to daily somatropin for annualized height velocity across all three indications. For example, in ISS, annualized height velocity was 10.2 cm/year versus 10.5 cm/year with daily somatropin.

3. Expansion into the substantial ISS population: Idiopathic short stature represents a particularly important opportunity because it substantially broadens the addressable population beyond diagnosed GHD. Novo Nordisk reported in September 2026 that ISS can affect up to 3% of children worldwide. The EMA's CHMP subsequently issued a positive opinion for once-weekly SOGROYA in European children with ISS, and if approved, Novo Nordisk stated it would be the first and only growth-hormone treatment approved for ISS in the EU. This European expansion could materially increase SOGROYA's eligible patient pool.

4. Strong commercial momentum and rising sales: SOGROYA's reported sales demonstrate rapid uptake. Novo Nordisk's 2025 investor presentation shows SOGROYA sales increasing from approximately DKK 1 billion in 2024 to DKK 2 billion in 2025, effectively doubling year over year. Combined Norditropin and SOGROYA human-growth-hormone sales reached DKK 6 billion in 2025, compared with DKK 5 billion in 2024. Novo Nordisk also reported that SOGROYA maintained leadership in the long-acting GH segment across its initial launch markets.

SOGROYA Recent Developments

In September 2026, Novo Nordisk welcomed a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), recommending once-weekly SOGROYA for children with idiopathic short stature (ISS) with persistent growth disturbance.

“SOGROYA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of SOGROYA for approved indication like Somatotropin deficiency in the 7MM. A detailed picture of SOGROYA’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the SOGROYA for approved indications. The SOGROYA market report provides insights about SOGROYA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current SOGROYA performance, future market assessments inclusive of the SOGROYA market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of SOGROYA sales forecasts, along with factors driving its market.

SOGROYA Drug Summary

SOGROYA is a long-acting recombinant human growth hormone (rhGH) analogue developed by Novo Nordisk for growth hormone replacement therapy. It is a modified form of human growth hormone designed to provide sustained exposure, allowing once-weekly subcutaneous administration instead of the daily injections required with conventional somatropin products. SOGROYA binds to the growth hormone receptor and activates the growth hormone/IGF-1 axis, thereby promoting growth and supporting the regulation of protein, lipid, carbohydrate, and bone metabolism. In the United States, SOGROYA is approved for the replacement of endogenous growth hormone in adults with growth hormone deficiency and for the treatment of growth failure in pediatric patients aged 2.5 years and older due to inadequate secretion of endogenous growth hormone. Its extended half-life is achieved through attachment of a side chain that facilitates reversible albumin binding and reduces renal clearance, enabling prolonged pharmacological activity. The drug is administered by subcutaneous injection using a prefilled pen, with dosing individualized according to the patient’s clinical response and treatment indication. SOGROYA represents an important advancement in growth hormone replacement by reducing injection frequency from daily administration to once weekly, potentially improving treatment convenience and adherence while maintaining the therapeutic effects of growth hormone. The report provides SOGROYA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the SOGROYA Market Report

The report provides insights into:

• A comprehensive product overview including the SOGROYA MoA, description, dosage and administration, research and development activities in approved indication like Somatotropin deficiency.
• Elaborated details on SOGROYA regulatory milestones and other development activities have been provided in SOGROYA market report.
• The report also highlights SOGROYA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The SOGROYA market report also covers the patents information, generic entry and impact on cost cut.
• The SOGROYA market report contains current and forecasted SOGROYA sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The SOGROYA market report also features the SWOT analysis with analyst views for SOGROYA in approved indications.

Methodology

The SOGROYA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SOGROYA Analytical Perspective by DelveInsight

• In-depth SOGROYA Market Assessment

This SOGROYA sales market forecast report provides a detailed market assessment of SOGROYA for approved indication like Somatotropin deficiency in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted SOGROYA sales data uptil 2034.

• SOGROYA Clinical Assessment

The SOGROYA market report provides the clinical trials information of SOGROYA for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

SOGROYA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

SOGROYA Market Potential & Revenue Forecast

• Projected market size for the SOGROYA and its key indications
• Estimated SOGROYA sales potential (SOGROYA peak sales forecasts)
• SOGROYA Pricing strategies and reimbursement landscape

SOGROYA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• SOGROYA Market positioning compared to existing treatments
• SOGROYA Strengths & weaknesses relative to competitors

SOGROYA Regulatory & Commercial Milestones

• SOGROYA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

SOGROYA Clinical Differentiation

• SOGROYA Efficacy & safety advantages over existing drugs
• SOGROYA Unique selling points

SOGROYA Market Report Highlights

• In the coming years, the SOGROYA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The SOGROYA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SOGROYA’s dominance.
• Other emerging products for Somatotropin deficiency are expected to give tough market competition to SOGROYA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SOGROYA in approved indications.
• Analyse SOGROYA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted SOGROYA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of SOGROYA in approved indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of SOGROYA? How strong is SOGROYA’s clinical and commercial performance?
• What is SOGROYA’s clinical trial status in each individual indications such as Somatotropin deficiency and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SOGROYA Manufacturers?
• What are the key designations that have been granted to SOGROYA for approved indications? How are they going to impact SOGROYA’s penetration in various geographies?
• What is the current and forecasted SOGROYA market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of SOGROYA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to SOGROYA for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is SOGROYA? What is the duration of therapy and what are the geographical variations in cost per patient?